Maxim Group Keeps Their Buy Rating on Viveve Medical Inc

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Viveve Medical Inc (NASDAQ: VIVE) today and set a price target of $9. The company’s shares opened today at $4.15.

Vendetti noted:

“Stress urinary incontinence (SUI) patients treated with the Viveve System experienced a 72.6% reduction in 1-hour pad weight at 6 months compared to baseline. All other outcome measures were positive and clinically meaningful, and there were no device-related safety issues reported.”

According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 13.6% and a 58.1% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.

Currently, the analyst consensus on Viveve Medical Inc is Strong Buy and the average price target is $7, representing a 68.7% upside.

In a report issued on June 4, Northland Securities also maintained a Buy rating on the stock with a $8 price target.

See today’s analyst top recommended stocks >>

Based on Viveve Medical Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.67 million. In comparison, last year the company had a GAAP net loss of $6.7 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.